Cabozantinib INN
Composition: Cabanib-20: Each film coated tablet contains Cabozantinib 20mg as Cabozantinib (S) Malate INN.
Cabanib-60: Each film coated tablet contains Cabozantinib 60mg as Cabozantinib (S) Malate INN.
Indications: Renal Cell Carcinoma: Cabozantinib is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). Hepatocellular Carcinoma: Cabozantinib is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Sorafenib.
Dosage and Administration: Recommended Dosage for Renal Cell Carcinoma: The recommended dosage of Cabozantinib is 60mg once daily without food until the patient no longer experiences clinical benefit or experiences unacceptable toxicity. Recommended Dosage for Hepatocellular Carcinoma: The recommended dosage of Cabozantinib is 60mg once daily without food until disease progression or unacceptable toxicity. Or, as directed by the
registered physicians.
Use in Pregnancy and Lactation: Cabozantinib can cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk.
Packing: Cabanib-20: Each container contains 30 tablets in a blister pack.
Cabanib-60: Each container contains 30 tablets in a blister pack.
